The study, which is evaluating the company’s immunotherapy eftilagimod alfa in combination with radiotherapy and MSD's KEYTRUDA (pembrolizumab) for resectable soft tissue sarcoma, significantly exceeded its prespecified pathologic response target. …
Immutep posts encouraging Phase 2 results as 'Efti' spurs robust anti-tumour activity
November 13, 2025 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - Series 5. Ep.30
August 28, 2026 - - Podcast -
Sandoz earns workplace recognition amid push for medicine access
August 28, 2026 - - Latest News -
Cheaper medicines save Australians $1.4 billion as pharmacists urge freeze for all patients
August 28, 2026 - - Latest News -
Mayne Pharma bets on women’s health and direct distribution after a difficult year
August 28, 2026 - - Latest News -
Patients Australia puts healthcare’s quiet achievers in the spotlight
August 28, 2026 - - Latest News -
Weight loss medicines drive revenue growth for Sigma and Wesfarmers Health
August 28, 2026 - - BioPharma -
Cathy Freeman to headline 2026 Patient’s Choice Awards
August 27, 2026 - - Latest News